Navigation Links
Soligenix Appoints Kevin Horgan, MD, as Chief Medical Officer
Date:2/1/2011

is research on human T cell differentiation, activation and migration with emphasis on integrin adhesion molecules provided a framework for subsequent validation of three therapeutic targets.  Dr. Horgan then did a fellowship in gastroenterology at University of California, Los Angeles (UCLA) and was an Assistant Professor of Medicine at UCLA, where his research focus was gastrointestinal inflammatory disorders.

"We are delighted to welcome Kevin to our team, as he will leverage his extensive drug development expertise in leading our GVHD and gastrointestinal clinical programs," said Christopher J. Schaber, PhD, President and CEO of Soligenix. "His clinical experience with gastrointestinal inflammation and a background in cellular immunology will be instrumental to us as we advance orBec® to Phase 3 completion in acute GI GVHD and beyond."  

About Soligenix, Inc.

Soligenix is a late-stage biopharmaceutical company developing products to treat life-threatening side effects of cancer treatments and serious gastrointestinal diseases, and vaccines for certain bioterrorism agents. Soligenix's lead product, orBec® (oral beclomethasone dipropionate), is a potent, locally acting corticosteroid being developed for the treatment of acute gastrointestinal Graft-versus-Host disease (GI GVHD), a common and potentially life-threatening complication of hematopoietic cell transplantation. orBec® is currently the subject of a $1.2 million FDA Orphan Products Grant-supported confirmatory Phase 3 clinical trial for the treatment of acute GI GVHD. Soligenix is also conducting a National Cancer Institute (NCI)-supported Phase 1/2 clinical trial of SGX201 in the prevention of acute radiation enteritis. Additionally, Soligenix has a Lipid Polymer Micelle (LPM™) drug delivery technology for the oral delivery of leuprolide for the treatment of prostate cancer and endometriosis.

Through its Biodefense Division, Soligenix is d
'/>"/>

SOURCE Soligenix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Soligenix Announces Publication of Positive Stability Results with RiVax(TM), its Vaccine Against Ricin Toxin
2. Soligenix Announces Publication of Positive Pre-Clinical Results with RiVax(TM), Its Vaccine Against Ricin Toxin
3. Soligenix Announces Initiation of a Phase 1/2 Clinical Trial of SGX201 for the Prevention of Acute Radiation Enteritis
4. Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines
5. Soligenix Announces Issuance of Hong Kong Patent for its LPM(TM) Oral Drug Delivery Technology
6. Soligenix Announces Publication of Positive Data Describing Protection from Mucosal and Systemic Ricin Intoxication by Intradermal RiVax™ Administration
7. Soligenix to Present at the OneMedForum Conference on Wednesday, June 30 at 2PM EDT
8. Soligenix Announces Award of $1.2 Million FDA Orphan Products Development Grant
9. Soligenix to Present at the Rodman & Renshaw Healthcare Conference on September 15, 2010 at 10AM EDT
10. Soligenix Announces Preliminary Results of its Phase 2 Clinical Trial of orBec® in the Prevention of Acute GVHD
11. Soligenix Announces Positive Preliminary Results of SGX202 in Radiation Injury
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... 2015 Breckenridge Pharmaceutical, Inc. announced today ... 0.1%. The U.S. Food and Drug Administration granted final approval ... is AB rated to Astelin®, a drug marketed ... spray) is a $69 million dollar generic market ... Azelastine HCl Nasal Solution is indicated for the ...
(Date:7/29/2015)... , 29. Juli 2015 ... wurde festgestellt, dass die tägliche Einnahme des ... die menschliche Darmflora anreichert und die Darmproduktion ... Die Studie umfasste die tägliche Einnahme von ... in Tablettenform unter Verwendung der patentierten Verabreichungstechnologie ...
(Date:7/29/2015)... 29, 2015 Cogentix Medical, Inc. (NASDAQ: CGNT ... market, will release financial results for the first quarter of ... market close on Monday, August 10, 2015. ... discuss these results on Monday, August 10, 2015 at 4:30 ... , President and Chief Executive Officer, and Brett Reynolds ...
Breaking Medicine Technology:Klinischer Nachweis erbracht, dass L. reuteri Probiotikum von Nutraceutix den Darm-Insulinmetabolismus moduliert 2Cogentix Medical to Announce First Quarter Fiscal 2016 Results on August 10, 2015 2
... LOS ANGELES, 16 April 2007- Antisoma announces ... are presented this,week at the Annual Meeting ... , AS1404-Avastin-paclitaxel triple combination highly effective,Antisoma's scientists ... triple,combination of the Company's vascular disrupting agent, ...
... - ZIOPHARM Oncology,Inc. (NASDAQ: ZIOP) announced today the ... of ZIO-201 (isophosphoramide mustard,- IPM) at the American ... Angeles. Data presented demonstrated oral availability,of ZIO-201 and ... with ifosfamide (IFOS) and cyclophosphamide resistant tumors.,An oral ...
Cached Medicine Technology:Data supporting three Antisoma programmes presented at AACR 2Data supporting three Antisoma programmes presented at AACR 3Data supporting three Antisoma programmes presented at AACR 4ZIOPHARM Presents Data on Orally Active ZIO-201 at AACR 2ZIOPHARM Presents Data on Orally Active ZIO-201 at AACR 3
(Date:7/29/2015)... ... ... " Core Organizer ” was featured on NewsWatch as part of its ... market for iOS, Android, and Windows. Joe Toohey, the host of AppWatch and technology ... anyone get organized. , Wouldn’t it be great if everyone could be a little ...
(Date:7/29/2015)... , ... July 29, 2015 , ... ... autism. Parents, educators and service providers of children living with autism will converge ... serve the growing demographic. , The National Autism Conference will be held ...
(Date:7/29/2015)... ... 2015 , ... According to The Spirits Business on July 16th, ... for stimulating and perpetuating alcohol use disorders. Humans have the same gene, which is ... academy of Sciences, and has given researchers inklings to explore Rsu1 in humans to ...
(Date:7/29/2015)... ... July 29, 2015 , ... With a new ... up with Stillwaters Cancer Support Services and announced a new charity campaign to ... family counseling, support groups, workshops and educational programs at no charge. Scott ...
(Date:7/29/2015)... ... July 29, 2015 , ... Wedding season is in full swing, which means bridal beauty ... of looking good on the big day. Every bride wants to look and feel beautiful, ... , According to a recent study by the American Academy of ...
Breaking Medicine News(10 mins):Health News:Get More Organized with the Core Organizer App 2Health News:Penn State Conference to Address Instruction, Success for Children with Autism 2Health News:Study Reveals Potential for Gene Manipulation to Stop Alcohol Addiction 2Health News:Study Reveals Potential for Gene Manipulation to Stop Alcohol Addiction 3Health News:Scott Campbell Agency and Nonprofit Stillwaters Cancer Support Services Initiate New Charity Campaign in Waukesha, WI to Provide Help for People Touched by Cancer 2Health News:Scott Campbell Agency and Nonprofit Stillwaters Cancer Support Services Initiate New Charity Campaign in Waukesha, WI to Provide Help for People Touched by Cancer 3Health News:Say I Do To Surgery: Bridal Beauty On The Rise According to New Survey 2Health News:Say I Do To Surgery: Bridal Beauty On The Rise According to New Survey 3
... cell therapies hold enormous potential to address some of ... However, the inability to target cells to tissues of ... To address this hurdle, researchers at Brigham and Women,s ... incorporate homing receptors onto the surface of cells. This ...
... , THURSDAY, Oct. 27 (HealthDay News) -- A ... of the arteries -- or atherosclerosis -- which can lead ... young men and 84 young women, aged 18 to 35, ... diabetes, smoking, high blood pressure, high blood cholesterol or family ...
... , THURSDAY, Oct. 27 (HealthDay News) -- Americans ... U.S. health officials said Thursday. Someone in the world ... Americans die of stroke every year. That number is about ... according to the U.S. Centers for Disease Control and Prevention. ...
... received a two-year, $452,218.00 grant from the national ... and Post-Breast Cancer Lymphedema." Post-breast cancer lymphedema ... distressing symptoms, is caused by injuries to the ... cancer treatment lengthen survival, LE has emerged as ...
... Researchers have identified a safer, more cost effective way ... an abdominal aortic aneurysm a common, often asymptomatic ... deadly. A new study done by investigators at ... invasive spinal, epidural and local/monitored anesthesia care (MAC) is ...
... sometimes referred to as a "mini stroke", were much less ... if their care was co-ordinated by a special hospital team. ... the November issue of the European Journal of Neurology ... Aarhus University Hospital in Denmark studied 306 patients admitted to ...
Cached Medicine News:Health News:Programming cells to home to specific tissues may enable more effective cell-based therapies 2Health News:Many Young Adults Unaware They're Developing Heart Disease 2Health News:U.S. Health Officials Urge Lifestyle Changes to Cut Stroke Risk 2Health News:NYU College of Nursing receives 450 thousand dollar NIH grant to research post-breast cancer lymphedema 2Health News:Less invasive anesthetic methods better for endovascular aneurysm repair 2Health News:Less invasive anesthetic methods better for endovascular aneurysm repair 3Health News:Hospital team significantly reduced risk of further vascular events after 'mini strokes' 2Health News:Hospital team significantly reduced risk of further vascular events after 'mini strokes' 3
9.5" overall length, 4.5" handle....
...
...
Medtronic neurosurgery external drainage and monitoring (EDM) products meet a variety of needs for CSF drainage and monitoring....
Medicine Products: